\-\ Texto\\:\\ \ \(0\)\
\-\ serum\\ gastrin\\ \\>1000\ \(0\)\
\-\ abnormally\\ increased\\ uptake\\ is\\ present\\ anterior\\ to\\ the\\ right\\ kidney\\ in\\ the\\ region\\ of\\ the\\ head\\ of\\ the\\ pancreas\\,\\ consistent\\ with\\ gastrinoma\\.\ \(0\)\
\-\ symptomatic\\ gastrinoma\\,\\ diagnosed\\ by\\ labaratory\\ and\\ octreoscan\\.\ \(0\)\
\-\ metastatic\\ neuroendocrine\\ tumor\\.\\ \\ gastrinoma\\ is\\ the\\ likely\\ etiology\\,\\ given\\ symptomatology\\,\\ abnormally\\ elevated\\ gastrin\\ levels\\,\\ and\\ the\\ location\\ of\\ the\\ primary\\ lesion\\.\\ \\ other\\ neuroendocrine\\ tumors\\ that\\ demonstrate\\ abnormally\\ increased\\ uptake\\ on\\ octreoscan\\ include\\ carcinoid\\,\\ pheochromocytoma\\,\\ neuroblastoma\\,\\ paraganglioma\\,\\ insulinoma\\,\\ vipoma\\,\\ medullary\\ thyroid\\ carcinoma\\,\\ etc\\.\ \(0\)\
\-\ chronic\\ nausea\\ and\\ vomitting\\ with\\ abnormally\\ high\\ serum\\ gastrin\\ levels\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ gastrin\\:\\ 0\\.41227037562234825\ \(0\)\
\-\ gastrinoma\\:\\ 0\\.39536644363882595\ \(0\)\
\-\ abnormally\\:\\ 0\\.379974279527308\ \(0\)\
\-\ octreoscan\\:\\ 0\\.29195573153887155\ \(0\)\
\-\ neuroendocrine\\:\\ 0\\.24843952861401056\ \(0\)\
\-\ serum\\:\\ 0\\.17132025484351435\ \(0\)\
\-\ labaratory\\:\\ 0\\.152767880777289\ \(0\)\
\-\ levels\\:\\ 0\\.15146509644553224\ \(0\)\
\-\ uptake\\:\\ 0\\.14690875320449878\ \(0\)\
\-\ vipoma\\:\\ 0\\.14597786576943578\ \(0\)\
\-\ insulinoma\\:\\ 0\\.13437025844506484\ \(0\)\
\-\ the\\:\\ 0\\.13342717122026723\ \(0\)\
\-\ vomitting\\:\\ 0\\.12421976430700528\ \(0\)\
\-\ 1000\\:\\ 0\\.1142082438920409\ \(0\)\
\-\ symptomatology\\:\\ 0\\.10857359989753346\ \(0\)\
\-\ pheochromocytoma\\:\\ 0\\.10798595232096236\ \(0\)\
\-\ paraganglioma\\:\\ 0\\.10390619905881657\ \(0\)\
\-\ increased\\:\\ 0\\.10331252043260605\ \(0\)\
\-\ carcinoid\\:\\ 0\\.10062821387633444\ \(0\)\
\-\ etc\\:\\ 0\\.09396270678421499\ \(0\)\
\-\ pancreas\\:\\ 0\\.08978193026663313\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.0877662914544789\ \(0\)\
\-\ medullary\\:\\ 0\\.08448447023085678\ \(0\)\
\-\ etiology\\:\\ 0\\.07695416949793939\ \(0\)\
\-\ thyroid\\:\\ 0\\.07507251254383858\ \(0\)\
\-\ symptomatic\\:\\ 0\\.07345437660224939\ \(0\)\
\-\ nausea\\:\\ 0\\.07338108879370954\ \(0\)\
\-\ tumors\\:\\ 0\\.07025492022732087\ \(0\)\
\-\ diagnosed\\:\\ 0\\.06919691133429562\ \(0\)\
\-\ kidney\\:\\ 0\\.06711095439436826\ \(0\)\
\-\ location\\:\\ 0\\.06651810531518555\ \(0\)\
\-\ given\\:\\ 0\\.06571261472672882\ \(0\)\
\-\ elevated\\:\\ 0\\.06512177708680425\ \(0\)\
\-\ and\\:\\ 0\\.05921822692396591\ \(0\)\
\-\ primary\\:\\ 0\\.058738573278796544\ \(0\)\
\-\ region\\:\\ 0\\.05713971358396708\ \(0\)\
\-\ carcinoma\\:\\ 0\\.05713971358396708\ \(0\)\
\-\ likely\\:\\ 0\\.05708435407066452\ \(0\)\
\-\ head\\:\\ 0\\.056974181057996745\ \(0\)\
\-\ include\\:\\ 0\\.05683747631905559\ \(0\)\
\-\ chronic\\:\\ 0\\.056701878513222795\ \(0\)\
\-\ of\\:\\ 0\\.0560824171845608\ \(0\)\
\-\ high\\:\\ 0\\.0542910786225028\ \(0\)\
\-\ anterior\\:\\ 0\\.05333648918285709\ \(0\)\
\-\ metastatic\\:\\ 0\\.05239157900917779\ \(0\)\
\-\ is\\:\\ 0\\.05232123436395205\ \(0\)\
\-\ consistent\\:\\ 0\\.051796732774746\ \(0\)\
\-\ tumor\\:\\ 0\\.04996597094346965\ \(0\)\
\-\ demonstrate\\:\\ 0\\.049661648257743995\ \(0\)\
\-\ other\\:\\ 0\\.0496085136678779\ \(0\)\
\-\ present\\:\\ 0\\.049017817496238486\ \(0\)\
\-\ lesion\\:\\ 0\\.04579759243145936\ \(0\)\
\-\ that\\:\\ 0\\.04145497589084193\ \(0\)\
\-\ by\\:\\ 0\\.040566148243340774\ \(0\)\
\-\ with\\:\\ 0\\.037410617610309914\ \(0\)\
\-\ right\\:\\ 0\\.031671031002535675\ \(0\)\
\-\ on\\:\\ 0\\.028850682552554418\ \(0\)\
\-\ to\\:\\ 0\\.02388147035712399\ \(0\)\
\-\ in\\:\\ 0\\.02376392580948645\ \(0\)\
